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I read with great interest the article by Cosci et al in a recent issue of your journal.1 The 
article provides for highly interesting reading and is very thought-provoking. Interest-
ingly, the past few years have seen the emergence of extensive data that establish a 
close association between the A118G single nucleotide polymorphism of the OPRM1 
gene and opioid, alcohol, and nicotine dependence.
A higher threshold to pain has been observed in individuals with the A118G variant.2 
Not surprisingly, Tan et al and Kapur et al have demonstrated a close association 
between the A118G variant and heroin dependence.3,4 Altered modulation of protein 
kinase A is responsible for this close association between the A118G variant of the 
OPRM1 gene and heroin dependency.5 A recent Japanese study has demonstrated that 
the presence of the A118G polymorphism is associated with an increased risk of addic-
tion to alcohol.6 Similarly, a recent Swedish study has demonstrated that the A118G 
variant is associated with an 11% risk of ethanol dependency.7 The treatment response 
to naltrexone in individuals with alcohol dependency varies greatly, depending on the 
presence or absence of the A118G variant.8 In females, there is a strong association 
between nicotine reinforcement and the A118G haplotype.9
The above examples illustrate a close association between A118G polymorphism 
and drug dependence. Hopefully, the coming years will see increased clinical applica-
tion of this close association in identifying and effectively treating individuals with 
this polymorphism.
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We thank Dr Kapoor for appreciating our review on nico-
tine dependence and psychological distress, and having 
taken it as a cue to reflect on the possible association 
between the A118G single nucleotide polymorphism of the 
OPRM1 gene and drug dependence. The literature offers 
several sets of data on this issue but, unfortunately, only a 
small number of studies have focused on nicotine depen-
dence. For instant, Ray et al recently noted that human mu 
opioid receptor (OPRM1 A118G) polymorphism is asso-
ciated with brain µ opioid receptor binding in smokers.1 
Further, Falcone et al found increased availability of the µ 
opioid receptor in the amygdala of smokers that could be 
contributory, emphasizing the motivation to smoke to obtain 
negative affective relief.2
Of course, we really hope that future investigations 
will clarify the possible association between smoking and 
genes, and as a further step, lead to the development of 
novel therapeutics. However, it is noteworthy that we are 
constantly reminded that genetics will transform and improve 
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our practice, but nothing has really come in the past two 
decades.3,4 Thus, psychopathology5 and clinical judgment,6 
still underappreciated as scientific tools but commonly used 
in clinical practice, can be a valid alternative approach to 
make the correct diagnosis and choose a tailored treatment 
for drug dependence, in particular for nicotine dependence. 
Indeed, good organization of clinical information (encom-
passing, eg, psychological distress and psychological well 
being), the use of a transfer station with repeated evaluations 
instead of diagnostic endpoints,7 and staging methods8 may 
guide assessment, treatment choice, and planning of follow-
up visits or interventions.7
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